|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Ries LA, Wingo PA, Miller DS, et al: The
annual report to the nation on the status of cancer, 1973–1997,
with a special section on colorectal cancer. Cancer. 88:2398–2424.
2000.
|
|
3
|
Tournigand C, André T, Achille E, et al:
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Falcone A, Ricci S, Brunetti I, et al:
Phase III trial of infusional fluorouracil, leucovorin,
oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional
fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line
treatment for metastatic colorectal cancer: the Gruppo Oncologico
Nord Ovest. J Clin Oncol. 25:1670–1676. 2007.
|
|
5
|
Saltz LB, Clarke S, Díaz-Rubio E, et al:
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized
phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Cutsem E, Köhne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
7
|
Bokemeyer C, Bondarenko I, Makhson A, et
al: Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Regnard JF, Grunenwald D, Spaggiari L, et
al: Surgical treatment of hepatic and pulmonary metastases from
colorectal cancers. Ann Thorac Surg. 66:214–219. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ballantyne GH and Quin J: Surgical
treatment of liver metastases in patients with colorectal cancer.
Cancer. 71:4252–4266. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Headrick JR, Miller DL, Nagorney DM, et
al: Surgical treatment of hepatic and pulmonary metastases from
colon cancer. Ann Thorac Surg. 71:975–980. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stang A, Fischbach R, Teichmann W,
Bokemeyer C and Braumann D: A systematic review on the clinical
benefit and role of radiofrequency ablation as treatment of
colorectal liver metastases. Eur J Cancer. 45:1748–1756. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nikfarjam M, Shereef S, Kimchi ET, et al:
Survival outcomes of patients with colorectal liver metastases
following hepatic resection or ablation in the era of effective
chemotherapy. Ann Surg Oncol. 16:1860–1867. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Inoue Y, Miki C, Hiro J, et al: Improved
survival using multi-modality therapy in patients with lung
metastases from colorectal cancer: a preliminary study. Oncol Rep.
14:1571–1576. 2005.PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
15
|
Kusunoki M, Yanagi H, Noda M, et al:
Results of pharmacokinetic modulating chemotherapy in combination
with hepatic arterial 5-fluorouracil infusion and oral UFT after
resection of hepatic colorectal metastases. Cancer. 89:1228–1235.
2000. View Article : Google Scholar
|
|
16
|
Grothey A, Sargent D, Goldberg RM and
Schmoll HJ: Survival of patients with advanced colorectal cancer
improves with the availability of fluorouracil-leucovorin,
irinotecan, and oxaliplatin in the course of treatment. J Clin
Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inoue Y, Miki C and Kusunoki M: Current
directions in chemotherapy for colorectal cancer. J Gastroenterol.
41:821–831. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Folprecht G, Grothey A, Alberts S, et al:
Neoadjuvant treatment of unresectable colorectal liver metastases:
correlation between tumour response and resection rates. Ann Oncol.
16:1311–1319. 2005. View Article : Google Scholar
|
|
19
|
Folprecht G, Gruenberger T, Bechstein WO,
et al: Tumour response and secondary resectability of colorectal
liver metastases following neoadjuvant chemotherapy with cetuximab:
the CELIM randomised phase 2 trial. Lancet Oncol. 11:38–47. 2010.
View Article : Google Scholar
|
